Androgens and prostate cancer: Are the descriptors valid?

被引：38

作者：

Roy-Burman, P

Tindall, DJ

Robins, DM

Greenberg, NM

Hendrix, MJC

Mohla, S

Getzenberg, RH

Isaacs, JT

Pienta, KJ

机构：

[1] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA

[2] Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA

[3] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA

[4] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA

[5] Northwestern Univ, Feinberg Sch Med, Childrens Mem Res Ctr, Chicago, IL 60611 USA

[6] NCI, Div Canc Biol, Rockville, MD USA

[7] Univ Pittsburgh, Inst Canc, Dept Urol, Pittsburgh, PA USA

[8] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Div Expt Therapeut, Baltimore, MD USA

[9] Univ Michigan, Ctr Canc, Dept Internal Med, Ann Arbor, MI 48109 USA

[10] Univ Michigan, Ctr Canc, Dept Urol, Ann Arbor, MI 48109 USA

来源：

CANCER BIOLOGY & THERAPY | 2005年 / 4卷 / 01期

关键词：

D O I：

10.4161/cbt.4.1.1563

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The term androgen-independent cancer has now become a misnomer. Given that the androgen receptor can be activated by even low androgen concentrations or via protein modifications or other protein-protein interactions, a growing prostate cancer has the chance of assuming an androgen depletion-independent state, without necessarily bypassing the androgen signaling processes. It is thus suggested that "androgen-independent (Al)" cancer should be more accurately termed "androgen depletion-independent (ADI)" cancer.

引用

页码：4 / 5

页数：2